Cities in lower tiers, particularly Tier 2 and Tier 3, signify the upcoming expansion of the healthcare sector

In a significant breakthrough, Zydus Therapeutics has announced positive topline results from the EPICS-III Phase 2(b)/3 Trial. The trial, conducted in patients with primary biliary cholangitis, saw Saroglitazar Magnesium, a drug developed by Zydus Therapeutics, demonstrating significant efficacy and safety in improving liver function markers.

Saroglitazar Magnesium is a potential treatment for primary biliary cholangitis, a liver disease that affects the small bile ducts. The positive results from the EPICS-III trial suggest that Saroglitazar Magnesium could offer hope to patients suffering from this condition.

The EPICS-III Phase 2(b)/3 Trial was a combination of Phase 2 and Phase 3 trials, indicating that it was a comprehensive study of the drug's safety and efficacy. The trial results were announced separately, ensuring transparency and maintaining the integrity of the research.

Meanwhile, the Madras Dyslexia Association has launched a new initiative to aid children. The 'Count on Me' toolkit is designed to support children with dyslexia and other learning difficulties. It's important to note that this initiative is independent of the EPICS-III Phase 2(b)/3 Trial and Zydus Therapeutics or Saroglitazar Magnesium.

In a separate development, Canon Medical Systems India has signed a Memorandum of Understanding (MoU) with the Rajiv Gandhi Cancer Institute. The agreement is for advanced collaborative projects, but it's not related to the EPICS-III Phase 2(b)/3 Trial.

Unfortunately, the Indian pharma and healthcare sector faced a funding drop in August 2025, with funding dropping by 82% to $47 million. However, this drop is not related to the EPICS-III Phase 2(b)/3 Trial or the positive results for Saroglitazar Magnesium.

In conclusion, the positive results from the EPICS-III Phase 2(b)/3 Trial mark a significant step forward in the treatment of primary biliary cholangitis. Saroglitazar Magnesium, developed by Zydus Therapeutics, has shown promise in improving liver function markers in patients with this condition. Meanwhile, the Madras Dyslexia Association's 'Count on Me' toolkit and the collaboration between Canon Medical Systems India and Rajiv Gandhi Cancer Institute continue to support children and cancer patients, respectively.